文献速递白血病MDS 与骨髓增殖性肿瘤

2310例继发性急性髓系白血病患者的治疗模式与结局:一项PETHEMA登记研究

Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
PubMed 文献 · Blood Adv · 2022-01-01

该研究基于PETHEMA登记分析2310例继发性急性髓系白血病(sAML)成人患者的特征、治疗模式与生存,并与新发AML比较。sAML患者年龄更大、ECOG≥2及高危细胞遗传学比例更高,强化化疗使用更少;sAML中位总生存(OS)短于新发AML(5.6 vs 10.9个月,P<.001),sAML为独立不良预后因素。

要点

  • sAML占全部AML的27.1%(2310/6211),以MDS-AML(44%)和治疗相关AML(25%)最常见。
  • sAML患者较新发AML年龄更大(中位69岁),ECOG≥2(35%)和高危细胞遗传学(40%)比例更高。
  • sAML中位OS短于新发AML(5.6 vs 10.9个月,P<.001),且为独立不良预后因素。

核心结论

  • 研究证实sAML发生率较高且临床特征不良,并确立其独立的不良预后价值。

研究设计与样本

  • 基于西班牙血液学治疗计划(PETHEMA)登记的分析,纳入6211例成人AML患者,其中新发AML 6211例中的72.9%(原文表述矛盾:6211应为总数,72.9%为新发比例)和sAML 2310例(27.1%)。

主要发现

  • sAML中位OS短于新发AML(5.6 vs 10.9个月,P<.001)。
  • 继发于血液病的sAML(MDS、MDS/MPN或MPN)中位OS短于t-AML和neo-AML(分别为5.3、6.1、5.7个月,P=.04)。
  • 强化化疗后,新发AML和neo-AML的中位OS分别为17.2个月和14.6个月。
  • 去甲基化药物治疗后,各类型AML之间未观察到OS差异。

关键数值与推荐

  • sAML亚型分布:MDS-AML 44%、MDS/MPN-AML 10%、MPN-AML 11%、t-AML 25%、neo-AML 9%。
  • sAML患者中位年龄69岁,ECOG≥2者35%,高危细胞遗传学40%,FLT3-ITD 11%,NPM1突变21%,接受强化化疗方案者38%(均P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Secondary acute myeloid leukemia (sAML) comprises a heterogeneous group of patients and is associated with poor overall survival (OS). We analyze the characteristics, treatment patterns, and outcomes of adult patients with sAML in the Programa Español de Tratamientos en Hematología (PETHEMA) registry. Overall, 6211 (72.9%) were de novo and 2310 (27.1%) had sAML, divided into myelodysplastic syndrome AML (MDS-AML, 44%), MDS/myeloproliferative AML (MDS/MPN-AML, 10%), MPN-AML (11%), therapy-related AML (t-AML, 25%), and antecedent neoplasia without prior chemotherapy/radiotherapy (neo-AML, 9%). Compared with de novo, patients with sAML were older (median age, 69 years), had more Eastern Cooperative Oncology Group ≥2 (35%) or high-risk cytogenetics (40%), less FMS-like tyrosine kinase 3 internal tandem duplication (11%), and nucleophosmin 1 (NPM1) mutations (21%) and received less intensive chemotherapy regimens (38%) (all P < .001). Median OS was higher for de novo than sAML (10.9 vs 5.6 months; P < .001) and shorter in sAML after hematologic disorder (MDS, MDS/MPN, or MPN) compared with t-AML and neo-AML (5.3 vs 6.1 vs 5.7 months, respectively; P = .04). After intensive chemotherapy, median OS was better among patients with de novo and neo-AML (17.2 and 14.6 months, respectively). No OS differences were observed after hypomethylating agents according to type of AML. sAML was an independent adverse prognostic factor for OS. We confirmed high prevalence and adverse features of sAML and established its independent adverse prognostic value. This trial was registered at www.clinicaltrials.gov as #NCT02607059.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022. PMID: 34794172. doi:10.1182/bloodadvances.2021005335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。